BACKGROUND: Antiglobulin responses are a significant limitation to the repeated use of murine monoclonal antibodies for treatment of transplant rejection. It is hoped that these might be largely overcome by using antibodies genetically engineered to resemble human antibodies. METHODS: We have compared the responses in patients treated with the CD52 monoclonal antibodies CAMPATH-1G (rat IgG2b) or its humanized derivative, CAMPATH-1H (human immunoglobulin G1). RESULTS: A majority of patients (15 of 17) made responses to the rat antibody, but there were no detectable responses to the humanized antibody (0 of 12). CONCLUSIONS: Although anti-idiotype responses are theoretically possible against humanized therapeutic antibodies and are especially likely to be provoked by cell-binding antibodies, these data show that humanization offers a significant reduction in immunogenicity, potentially allowing repeat courses of treatment.
BACKGROUND: Antiglobulin responses are a significant limitation to the repeated use of murine monoclonal antibodies for treatment of transplant rejection. It is hoped that these might be largely overcome by using antibodies genetically engineered to resemble human antibodies. METHODS: We have compared the responses in patients treated with the CD52 monoclonal antibodies CAMPATH-1G (rat IgG2b) or its humanized derivative, CAMPATH-1H (human immunoglobulin G1). RESULTS: A majority of patients (15 of 17) made responses to the rat antibody, but there were no detectable responses to the humanized antibody (0 of 12). CONCLUSIONS: Although anti-idiotype responses are theoretically possible against humanized therapeutic antibodies and are especially likely to be provoked by cell-binding antibodies, these data show that humanization offers a significant reduction in immunogenicity, potentially allowing repeat courses of treatment.
Authors: Ugo Boggi; Romano Danesi; Fabio Vistoli; Marco Del Chiaro; Stefano Signori; Piero Marchetti; Mario Del Tacca; Franco Mosca Journal: Drug Saf Date: 2004 Impact factor: 5.606
Authors: Nicolas Dubuisson; David Baker; Angray S Kang; Gareth Pryce; Monica Marta; Leo H Visser; Werner E Hofmann; Sharmilee Gnanapavan; Gavin Giovannoni; Klaus Schmierer Journal: Immunology Date: 2018-01-04 Impact factor: 7.397
Authors: Marieke van der Zwan; Marian C Clahsen-Van Groningen; Martijn W F van den Hoogen; Marcia M L Kho; Joke I Roodnat; Katya A L Mauff; Dave L Roelen; Madelon van Agteren; Carla C Baan; Dennis A Hesselink Journal: Front Immunol Date: 2020-07-03 Impact factor: 7.561
Authors: David Baker; Liaqat Ali; Gauri Saxena; Gareth Pryce; Meleri Jones; Klaus Schmierer; Gavin Giovannoni; Sharmilee Gnanapavan; Kathleen C Munger; Lawrence Samkoff; Andrew Goodman; Angray S Kang Journal: Front Immunol Date: 2020-02-14 Impact factor: 7.561